Jane Street Group LLC Buys New Shares in Inhibrx, Inc. (NASDAQ:INBX)

Jane Street Group LLC purchased a new position in shares of Inhibrx, Inc. (NASDAQ:INBX) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 88,419 shares of the company’s stock, valued at approximately $1,362,000. Jane Street Group LLC owned approximately 0.61% of Inhibrx at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. HighTower Advisors LLC bought a new position in Inhibrx during the fourth quarter worth about $12,039,000. Walleye Capital LLC bought a new position in shares of Inhibrx during the 4th quarter worth approximately $8,932,000. Slotnik Capital LLC bought a new position in shares of Inhibrx during the 4th quarter worth approximately $5,975,000. Geode Capital Management LLC acquired a new position in shares of Inhibrx during the 4th quarter worth approximately $3,930,000. Finally, Castalian Partners LLC bought a new stake in Inhibrx in the 4th quarter valued at $2,950,000. Institutional investors and hedge funds own 82.46% of the company’s stock.

Inhibrx Stock Performance

Shares of INBX stock opened at $12.47 on Tuesday. Inhibrx, Inc. has a 52 week low of $10.80 and a 52 week high of $34.71. The company has a market capitalization of $180.52 million and a price-to-earnings ratio of 0.11. The company has a 50-day simple moving average of $12.59 and a 200 day simple moving average of $13.61.

Inhibrx (NASDAQ:INBX) last posted its earnings results on Wednesday, May 14th. The company reported ($2.80) EPS for the quarter, missing the consensus estimate of ($2.55) by ($0.25). Sell-side analysts forecast that Inhibrx, Inc. will post 104.88 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, JMP Securities reaffirmed a “market perform” rating on shares of Inhibrx in a research report on Thursday, May 15th.

Inhibrx Company Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.